Epidemiology of geographic atrophy and its precursor features of intermediate age‐related macular degeneration

Abstract

Globally age‐related macular degeneration (AMD) is a leading cause of blindness with a significant impact on quality of life. Geographic atrophy (GA) is the atrophic late form of AMD and its prevalence increases markedly with age with around 1 in 5 persons aged 85 and above having GA in at least one eye. Bilateral GA leads to severe visual impairment thus posing a significant burden on patients, careers and health providers. The incidence and prevalence of GA varies across different geographic regions, with the highest rates in those of European ancestry. Although heterogeneity in definitions of GA and reporting strategy can explain some of the discrepancies, the data overall are consistent in showing a lower prevalence in other ethnicities such as those of Asian heritage. This is at present unexplained but thought to be due to the existence of protective factors such as differences in eye pigmentation, diet, environmental exposures and genetic variability. This review covers key aspects of the prevalence and incidence of the ocular precursor features of GA (large drusen, pigmentary abnormalities and reticular pseudo‐drusen), the late stage of GA and factors that have been known to be associated with modifying risk including systemic, demographic, environment, genetic and ocular. Understanding the global epidemiology scenario is crucial for the prevention of and management of patients with GA.

The Analysis Study of Visual Impairment and Blindness Due to Macular Diseases: A Comprehensive Systematic Review

“…Future studies should explore the drivers of progression to GA across different ancestries and regions, aiming to develop prevention strategies and resource allocation strategies. 16 The review by Cheema & Cheema emphasizes how anti-VEGF medications can significantly improve DME, the primary cause of visual impairment in diabetics. Important clinical trials that have demonstrated their efficacy include VISTA-DME, VIVID-DME, and RIDE/RISE.…”

Macular Neovascularization Secondary to Subclinical Angioid Streaks in Age-Related Macular Degeneration: Treatment Response to Anti-VEGF at 2-Year Follow-up

“…Furthermore, the group of AMD with subliclinical AS was characterized by the presence of RPD in almost all cases and a significantly thinner choroidal thickness compared to the control group. Both these two features are known to be significant risk factors for the development of atrophy [ 26 – 28 ].…”

Cholesterol metabolism: physiological regulation and diseases

“…AMD is the leading cause of blindness worldwide and has a significant impact on quality of life 175 . About 80% of AMD patients are diagnosed with early dry subtypes, characterized by the formation of drusen under RPE, thickening of the Bruch membrane, and accumulation of lipofuscin in RPE 176 .…”